{"nctId":"NCT00189202","briefTitle":"Efficacy of Sirolimus-Based, Steroid Avoidance Immunosuppression African Americans","startDateStruct":{"date":"2004-08"},"conditions":["End Stage Renal Disease","Kidney Transplantation"],"count":49,"armGroups":[{"label":"Sirolimus, steroid avoidance arm","type":"EXPERIMENTAL","interventionNames":["Drug: Sirolimus"]}],"interventions":[{"name":"Sirolimus","otherNames":["Rapamune"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* African American recipient race\n* Solitary cadaveric or living donor renal transplantation\n* Age â‰¥18years at the time of transplantation\n* Negative pregnancy serum test in females with childbearing potential\n\nExclusion Criteria:\n\n* Age \\< 18 years at the time of transplantation\n* Multi-organ transplant recipient\n* Currently taking steroids\n* White Blood Cell Count \\< 3,000\n* Platelet count \\< 100,000\n* Triglycerides \\>400mg/dL\n* Cholesterol \\> 350 mg/dL\n* Unwillingness to comply with study procedures\n* Allergic reaction to sirolimus Allergy to polyclonal antilymphocyte drugs (Thymoglobulin)","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Cumulative One-year Acute Rejection Rates","description":"To test the efficacy of Sirolimus (SRL)-based steroid avoidance regimen in high risk de novo renal allograft recipients. Efficacy endpoints for this objective is: cumulative one-year acute rejection rates of the transplant","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null}]}]}]},{"type":"PRIMARY","title":"One-year Graft Survival","description":"To test the efficacy of SRL-based steroid avoidance regimen in high risk de novo renal allograft recipients. Efficacy endpoints for this objective is: one-year graft survival","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"42","spread":null}]}]}]},{"type":"PRIMARY","title":"One-year Patient Survival","description":"To test the efficacy of SRL-based steroid avoidance regimen in high risk de novo renal allograft recipients. Efficacy endpoints for this objective is: one-year patient survival","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"44","spread":null}]}]}]},{"type":"SECONDARY","title":"Incidence of Post Transplant Diabetes","description":"To determine whether SRL-based steroid avoidance maintenance regimen is associated with decreased rates of metabolic complications. Endpoint is incidence of posttransplant diabetes mellitus","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null}]}]}]},{"type":"SECONDARY","title":"Drug-treated Dyslipidemic Syndrome","description":"To determine whether SRL-based steroid avoidance maintenance regimen is associated with decreased rates of metabolic complications. Endpoint is drug-treated dyslipidemic syndrome","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21","spread":null}]}]}]},{"type":"SECONDARY","title":"Blood Pressure Control","description":"To determine whether SRL-based steroid avoidance maintenance regimen is associated with decreased rates of metabolic complications. Endpoint is number of people who had their blood pressure in the target control range with or without medication","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"34","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":44},"commonTop":[]}}}